Platelet Transfusion — Dose & CCI
Hướng dẫn chi tiết sắp ra mắt
Chúng tôi đang chuẩn bị hướng dẫn giáo dục toàn diện cho Platelet Transfusion Calculator. Quay lại sớm để xem giải thích từng bước, công thức, ví dụ thực tế và mẹo từ chuyên gia.
Platelet transfusion is the administration of donor platelets to patients with thrombocytopenia or platelet dysfunction to prevent or treat bleeding. Platelets are small anucleate cell fragments critical to primary haemostasis — they adhere to damaged vascular endothelium, activate, and aggregate to form a platelet plug before the coagulation cascade consolidates this into a fibrin clot. The standard adult therapeutic dose (ATD) consists of either 4–6 units of pooled buffy-coat-derived platelets or a single apheresis platelet unit, both providing approximately 250–350 × 10^9 platelets and raising the platelet count by 20,000–40,000/mcL in a 70 kg adult without refractoriness. Platelet transfusion thresholds depend on the clinical setting: prophylactic transfusion is given at counts <10,000/mcL in stable haematology patients and <20,000/mcL in those with fever or minor procedures; higher thresholds (50,000–100,000/mcL) are used for invasive procedures or surgery. The Corrected Count Increment (CCI) is the key metric for assessing transfusion efficacy: CCI = (Post-transfusion count − Pre-transfusion count) × BSA (m²) / (Platelets transfused × 10^11). A CCI greater than 7,500 at 1 hour post-transfusion indicates an adequate response. A CCI below 7,500 on two consecutive transfusions suggests platelet refractoriness, most commonly from HLA alloimmunisation, which requires HLA-matched or crossmatch-compatible platelets. Other causes of poor platelet increment include sepsis, splenomegaly, DIC, and fever. Understanding the CCI is essential for efficiently managing haemato-oncology patients on chronic platelet support.
Dose: 1 Adult Therapeutic Dose (ATD) = 4–6 pooled units or 1 apheresis unit CCI = (Post-platelet count − Pre-platelet count [/mcL]) × BSA (m²) / (Platelets transfused × 10^11) CCI >7500 at 1 hour = adequate response CCI <7500 on 2 consecutive occasions = platelet refractoriness
- 1Confirm indication: thrombocytopenia with active bleeding, prophylactic threshold (<10,000/mcL stable, <20,000/mcL fever/procedure), or platelet dysfunction.
- 2Record pre-transfusion platelet count, patient weight, and body surface area (BSA) for CCI calculation.
- 3Order 1 ATD (4–6 pooled donor units or 1 apheresis unit). Request ABO-compatible platelets; Rh-negative platelets for Rh-negative females of childbearing age.
- 4Administer platelets over 15–30 minutes. Observe for transfusion reactions during and after infusion.
- 5Check post-transfusion platelet count at 1 hour and 24 hours to assess increment.
- 6Calculate CCI using the formula. CCI >7,500 at 1 hour = adequate response; CCI <7,500 = investigate refractoriness.
- 7If refractory: check for HLA antibodies, request HLA-matched or crossmatch-compatible platelets from the blood bank, and investigate for non-immune causes (DIC, sepsis, splenomegaly).
CCI >7,500 — excellent response; no refractoriness
The platelet count rose by 34,000/mcL and the CCI is well above the 7,500 threshold. This indicates normal platelet survival and no immune-mediated destruction. Standard dosing interval can be maintained.
CCI <7,500 — poor increment; refractoriness suspected
The minimal rise in platelet count despite a full ATD, with a CCI of only 1,943, is consistent with immune-mediated platelet destruction from HLA antibodies. HLA antibody screen should be requested and HLA-matched platelets sourced from the national blood service.
Transfuse shortly before surgery; recheck count immediately pre-operatively
For major surgery, a platelet count of at least 80,000/mcL is generally required. Each ATD raises count by approximately 20,000–40,000/mcL. Two ATDs given 30 minutes before surgery with immediate pre-operative count verification is the standard approach.
Low CCI without HLA antibodies — non-immune cause; treat underlying sepsis
Sepsis causes platelet consumption and splenomegaly traps transfused platelets, reducing the increment. As HLA antibodies are absent, immune refractoriness is excluded. Treating the infection is the priority; higher transfusion thresholds and more frequent transfusions may be temporarily needed.
Haemato-oncology wards managing chemotherapy-induced thrombocytopenia with twice-weekly prophylactic platelet counts and transfusion thresholds., representing an important application area for the Platelet Transfusion in professional and analytical contexts where accurate platelet transfusion calculations directly support informed decision-making, strategic planning, and performance optimization
Intensive care units monitoring platelet consumption in DIC complicating sepsis, trauma, or obstetric emergencies., representing an important application area for the Platelet Transfusion in professional and analytical contexts where accurate platelet transfusion calculations directly support informed decision-making, strategic planning, and performance optimization
Cardiac surgical units transfusing platelets post-cardiopulmonary bypass to reverse bypass-induced platelet dysfunction and prevent re-operation for bleeding., representing an important application area for the Platelet Transfusion in professional and analytical contexts where accurate platelet transfusion calculations directly support informed decision-making, strategic planning, and performance optimization
Neonatal ICUs managing NAIT with HPA-matched platelets to prevent intracranial haemorrhage in affected neonates., representing an important application area for the Platelet Transfusion in professional and analytical contexts where accurate platelet transfusion calculations directly support informed decision-making, strategic planning, and performance optimization
Blood banks using CCI data to identify HLA-alloimmunised patients and coordinate procurement of compatible donor platelets for refractory cases., representing an important application area for the Platelet Transfusion in professional and analytical contexts where accurate platelet transfusion calculations directly support informed decision-making, strategic planning, and performance optimization
Immune Thrombocytopenic Purpura (ITP)
{'title': 'Immune Thrombocytopenic Purpura (ITP)', 'body': 'In ITP, platelet transfusion is generally ineffective because transfused platelets are rapidly destroyed by anti-platelet antibodies. Transfusion is reserved for life-threatening bleeding and given at high doses (2 ATDs) as a temporary measure. Specific treatments (IVIG, corticosteroids, thrombopoietin receptor agonists) are the mainstay of management.'}
Dengue Fever
{'title': 'Dengue Fever', 'body': 'Dengue causes a self-limiting thrombocytopenia rarely requiring transfusion unless the count falls below 10,000/mcL with active bleeding. Over-transfusion with platelets is associated with worse outcomes in dengue due to increased intravascular volume and potential immune activation. WHO guidelines advise against prophylactic platelet transfusion in dengue without clinical bleeding.'}
When platelet transfusion input values approach zero or become negative in the
When platelet transfusion input values approach zero or become negative in the Platelet Transfusion, mathematical behavior changes significantly. Zero values may cause division-by-zero errors or trivially zero results, while negative inputs may yield mathematically valid but practically meaningless outputs in platelet transfusion contexts. Professional users should validate that all inputs fall within physically or financially meaningful ranges before interpreting results. Negative or zero values often indicate data entry errors or exceptional platelet transfusion circumstances requiring separate analytical treatment.
Post-Cardiopulmonary Bypass
In the Platelet Transfusion, this scenario requires additional caution when interpreting platelet transfusion results. The standard formula may not fully account for all factors present in this edge case, and supplementary analysis or expert consultation may be warranted. Professional best practice involves documenting assumptions, running sensitivity analyses, and cross-referencing results with alternative methods when platelet transfusion calculations fall into non-standard territory.
Thrombotic Microangiopathy (TMA)
In the Platelet Transfusion, this scenario requires additional caution when interpreting platelet transfusion results. The standard formula may not fully account for all factors present in this edge case, and supplementary analysis or expert consultation may be warranted. Professional best practice involves documenting assumptions, running sensitivity analyses, and cross-referencing results with alternative methods when platelet transfusion calculations fall into non-standard territory.
| Clinical Setting | Platelet Threshold | Target Count | Notes |
|---|---|---|---|
| Stable haematology patient (prophylactic) | <10,000/mcL | >10,000/mcL | Single ATD; restrict to once daily |
| Fever or minor bleeding | <20,000/mcL | >20,000/mcL | More frequent monitoring |
| Central line insertion / minor procedure | <50,000/mcL | >50,000/mcL | Give shortly before procedure |
| Major surgery / epidural | <80,000/mcL | >80,000/mcL | Recheck immediately pre-operatively |
| Neurosurgery / intracranial procedure | <100,000/mcL | >100,000/mcL | Consider continuous monitoring |
| Active major bleeding | Any count | >50,000–100,000/mcL | Give empirically in massive haemorrhage protocol |
What is the difference between pooled and apheresis platelets?
Pooled platelets are made by combining buffy coats from 4–6 whole blood donations. Apheresis (single-donor) platelets are collected from one donor using a cell separator. Both provide a similar platelet dose per ATD. Apheresis units reduce donor exposure (lower alloimmunisation risk), are preferred for HLA-matched products, and are the format of choice for neonatal or immunocompromised patients.
What is platelet refractoriness and how is it diagnosed?
Platelet refractoriness is defined as two consecutive low CCI values (<7,500 at 1 hour) using ABO-compatible, fresh platelets. Immune causes include HLA antibodies (most common), HPA (human platelet antigen) antibodies, and ABO incompatibility. Non-immune causes include sepsis, DIC, splenomegaly, fever, and drug effects. This is particularly important in the context of platelet transfusion calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise platelet transfusion computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
What is the prophylactic transfusion threshold in haemato-oncology?
Most guidelines recommend prophylactic transfusion at platelet count <10,000/mcL in stable haematology inpatients (e.g., post-chemotherapy). The threshold rises to 20,000/mcL with fever, minor bleeding, or invasive procedures such as central line insertion. For lumbar puncture or bone marrow biopsy, a count >50,000/mcL is usually required. This is particularly important in the context of platelet transfusion calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise platelet transfusion computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
Should platelets be ABO compatible?
ABO compatibility is preferred because platelets carry ABO antigens, and transfusing incompatible platelets can cause minor haemolytic reactions and reduce platelet increment. In emergencies, ABO-incompatible platelets can be given but may result in lower CCI. ABO-compatible platelets should always be used in neonates. This is particularly important in the context of platelet transfusion calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise platelet transfusion computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
When should Rh-negative platelets be given?
Rh(D)-negative platelets should be given to Rh(D)-negative females of childbearing potential to prevent Rh sensitisation (caused by the small amount of red cell contamination in platelet products). If Rh-positive platelets are unavoidable, anti-D immunoglobulin (250 IU) should be given within 72 hours. This is particularly important in the context of platelet transfusion calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise platelet transfusion computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
What is the 24-hour CCI used for?
The 24-hour CCI reflects platelet survival rather than the initial distribution. A low 1-hour CCI with a reasonable 24-hour CCI suggests immune destruction occurring rapidly post-transfusion. A low 24-hour CCI with a normal 1-hour CCI is more consistent with non-immune consumption (sepsis, DIC). Both time points together provide a more complete picture.
Can platelet transfusion worsen thrombosis in HIT?
Yes. In heparin-induced thrombocytopenia (HIT), platelet transfusion is generally contraindicated because it can fuel the prothrombotic state and worsen thrombosis. Platelets should only be given in HIT with life-threatening bleeding. Alternative anticoagulation with argatroban or danaparoid is the priority. This is particularly important in the context of platelet transfusion calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise platelet transfusion computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
How long do transfused platelets survive?
Normal platelet lifespan is 8–10 days. Transfused platelets survive approximately 3–5 days in the absence of immune destruction or consumption. In conditions of high platelet consumption (DIC, sepsis, ITP), survival may be as short as hours. This determines the frequency of repeat transfusion in intensive care settings. This is particularly important in the context of platelet transfusion calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise platelet transfusion computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
Mẹo Chuyên Nghiệp
When platelet refractoriness is suspected, always calculate the CCI from the 1-hour post-transfusion count and look for both immune and non-immune causes before ordering expensive HLA-matched products. Correcting reversible non-immune factors (treating sepsis, reviewing potentially causative drugs, addressing DIC) is cost-effective and may restore adequate increments without specialist products.
Bạn có biết?
Platelets were only recognised as distinct cellular elements of blood in the 1880s by Giulio Bizzozero, who coined the term 'blood platelets'. Before this discovery, the clotting mechanism was attributed entirely to red blood cells. The first platelet transfusion was not performed until 1910, and platelet concentrates as a routine blood product only became available in the 1950s.
Tài liệu tham khảo
- ›BCSH Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122(1):10-23.
- ›Kaufman RM et al. Platelet Transfusion: A Clinical Practice Guideline from the AABB. Ann Intern Med. 2015;162(3):205-213.
- ›Slichter SJ. Platelet refractoriness and alloimmunization. Leukemia. 1998;12(Suppl 1):S51-55.
- ›NHS Blood and Transplant. Platelet transfusion — clinical and laboratory guidance. 2021.